Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis

Untreated patients with multiple sclerosis: a study of French expert centers.

(2021) Xavier Moisset et al.   EUROPEAN JOURNAL OF NEUROLOGY

Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis

(2020) Luca Prosperini et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions

(2020) Jean-Christophe Brisset et al.   JOURNAL OF NEURORADIOLOGY

Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability

(2020) Anne Kerbrat et al.   BRAIN

Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis

(2020) Elena Tsantes et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

(2020) Ludwig Kappos et al.   JAMA Neurology

Detection of disability worsening in relapsing‐remitting multiple sclerosis patients. A real‐world roving EDSS‐Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

(2020) Vito Lepore et al.   EUROPEAN JOURNAL OF NEUROLOGY

Targeting progression in multiple sclerosis — an update

(2019) Maria A. Rocca et al.   Nature Reviews Neurology

Spatial distribution of multiple sclerosis lesions in the cervical spinal cord

(2019) Dominique Eden et al.   BRAIN

Silent Progression in Disease Activity-Free Relapsing Multiple Sclerosis

(2019) et al.   ANNALS OF NEUROLOGY

Classifying silent progression in relapsing–remitting MS

(2019) Massimo Filippi et al.   Nature Reviews Neurology

‘No evidence of disease activity’ - is it an appropriate surrogate in multiple sclerosis?

(2018) H. Hegen et al.   EUROPEAN JOURNAL OF NEUROLOGY

Progressive Forms of Multiple Sclerosis

(2018) Burcu Zeydan et al.   NEUROLOGIC CLINICS

Predicting the profile of increasing disability in multiple sclerosis

(2018) Valentina Tomassini et al.   Multiple Sclerosis Journal

Unraveling treatment response in multiple sclerosis

(2018) Claudio Gasperini et al.   NEUROLOGY

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

(2017) Ludwig Kappos et al.   Multiple Sclerosis Journal

Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients

(2017) Jordi Río et al.   Multiple Sclerosis Journal

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Practical recommendations for reporting Fine-Gray model analyses for competing risk data

(2017) Peter C. Austin et al.   STATISTICS IN MEDICINE

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

(2017) Ludwig Kappos et al.   Multiple Sclerosis Journal

Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients

(2017) Jordi Río et al.   Multiple Sclerosis Journal

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab

(2017) Jan Fagius et al.   Multiple Sclerosis and Related Disorders

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments

(2017) Ann Marie Weideman et al.   Frontiers in Neurology

Long-term evolution of multiple sclerosis disability in the treatment era

(2016) et al.   ANNALS OF NEUROLOGY

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

(2016) Ilya Kister et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

(2016) Tomas Uher et al.   Multiple Sclerosis Journal

Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors

(2016) Gabriel Bsteh et al.   Multiple Sclerosis Journal

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

(2016) Ludwig Kappos et al.   Multiple Sclerosis Journal

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

(2016) Tomas Uher et al.   Multiple Sclerosis Journal

Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors

(2016) Gabriel Bsteh et al.   Multiple Sclerosis Journal

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

(2016) Ludwig Kappos et al.   Multiple Sclerosis Journal

Treatment withdrawal in relapsing−remitting multiple sclerosis: a retrospective cohort study

(2015) G. Lus et al.   EUROPEAN JOURNAL OF NEUROLOGY

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

(2015)   Nature Reviews Neurology

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients

(2013) Massimo Filippi et al.   NEUROLOGICAL SCIENCES

Reliability of Classifying Multiple Sclerosis Disease Activity Using Magnetic Resonance Imaging in a Multiple Sclerosis Clinic

(2012) Ebru Erbayat Altay et al.   JAMA Neurology

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity

(2011) Małgorzata Siger et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES